DK1032379T3 - Præparat med azelainsyre - Google Patents

Præparat med azelainsyre

Info

Publication number
DK1032379T3
DK1032379T3 DK98962351T DK98962351T DK1032379T3 DK 1032379 T3 DK1032379 T3 DK 1032379T3 DK 98962351 T DK98962351 T DK 98962351T DK 98962351 T DK98962351 T DK 98962351T DK 1032379 T3 DK1032379 T3 DK 1032379T3
Authority
DK
Denmark
Prior art keywords
azelaic acid
preparation
composition
presbyderma
triacylglyceride
Prior art date
Application number
DK98962351T
Other languages
English (en)
Inventor
Patrick Franke
Clemens Guenther
Jutta Riedl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217979&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1032379(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1032379T3 publication Critical patent/DK1032379T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
DK98962351T 1997-11-19 1998-11-18 Præparat med azelainsyre DK1032379T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19753044 1997-11-19
US7485098P 1998-02-12 1998-02-12
DE19808086 1998-02-20
PCT/EP1998/007370 WO1999025332A1 (de) 1997-11-19 1998-11-18 Zusammensetzung mit azelainsäure

Publications (1)

Publication Number Publication Date
DK1032379T3 true DK1032379T3 (da) 2002-04-02

Family

ID=27217979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98962351T DK1032379T3 (da) 1997-11-19 1998-11-18 Præparat med azelainsyre

Country Status (21)

Country Link
US (1) US6534070B1 (da)
EP (1) EP1032379B1 (da)
JP (1) JP3867123B2 (da)
KR (1) KR100534511B1 (da)
AT (1) ATE210438T1 (da)
AU (1) AU743437B2 (da)
BR (1) BR9814214B1 (da)
CA (1) CA2311128C (da)
CZ (1) CZ299116B6 (da)
DE (2) DE59802473D1 (da)
DK (1) DK1032379T3 (da)
ES (1) ES2169566T3 (da)
HU (1) HU226592B1 (da)
IL (1) IL136101A (da)
IS (1) IS2257B (da)
NO (1) NO327712B1 (da)
PL (1) PL202454B1 (da)
PT (1) PT1032379E (da)
SK (1) SK284338B6 (da)
TR (1) TR200001393T2 (da)
WO (1) WO1999025332A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient
WO2004108143A1 (de) * 2003-06-10 2004-12-16 Schering Aktiengesellschaft Zusammensetzung aus alkandicarbonsäuren und einem pharmazeutischen wirkstoff
DE50305909D1 (de) * 2003-10-13 2007-01-18 Salama Zoser B Pharmazeutische Zusammensetzung umfassend Oxoplatin und dessen Salze
DE10356288B4 (de) 2003-11-28 2014-04-03 Siemens Aktiengesellschaft Röntgendetektorlade
EP1861067A2 (en) * 2005-03-09 2007-12-05 Combe Incorporated Stable mixed emulsions comprising semisolid dispersions of at least two discrete and distinctly different particle size ranges
EP1926466A2 (en) * 2005-09-19 2008-06-04 Combe Incorporated Stable emulsion systems with high salt tolerance
KR100861978B1 (ko) * 2007-03-22 2008-10-07 한국콜마 주식회사 아젤라산을 이용한 여드름 치료용 화장료 조성물 및 그 제조방법
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
EP2201930A1 (en) * 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
PL217786B1 (pl) * 2009-05-28 2014-08-29 P P F Hasco Lek Spółka Akcyjna Żel z kwasem azelainowym i sposób wytwarzania żelu z kwasem azelainowym
CN102770162B (zh) 2009-08-21 2016-09-28 靶向递送技术有限公司 囊泡制剂
DE102010021671A1 (de) * 2010-05-27 2011-12-01 Intendis Gmbh Azelainsäurehaltige Formulierung mit Pigmentzusatz
GB201205642D0 (en) * 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3811081A1 (de) 1988-03-30 1989-10-12 Schering Ag Verwendung von topisch applizierbaren praeparaten zur behandlung der altershaut
ATE117665T1 (de) * 1990-11-14 1995-02-15 Oreal Amphiphile, nichtionische derivate des glycerins sowie die entsprechenden zwischenprodukte, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
GB9316323D0 (en) * 1993-08-06 1993-09-22 Procter & Gamble Cosmetic compositions
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5547989A (en) 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
UY24246A1 (es) 1995-06-06 1996-06-14 Neutrogena Corp Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado

Also Published As

Publication number Publication date
AU743437B2 (en) 2002-01-24
BR9814214A (pt) 2000-10-03
JP3867123B2 (ja) 2007-01-10
WO1999025332A1 (de) 1999-05-27
IS2257B (is) 2007-06-15
PL202454B1 (pl) 2009-06-30
PT1032379E (pt) 2002-06-28
JP2001522879A (ja) 2001-11-20
TR200001393T2 (tr) 2000-10-23
IL136101A (en) 2005-08-31
CA2311128A1 (en) 1999-05-27
CZ20001844A3 (cs) 2000-10-11
US6534070B1 (en) 2003-03-18
AU1755199A (en) 1999-06-07
HUP0004375A2 (hu) 2001-08-28
NO327712B1 (no) 2009-09-14
NO20002487D0 (no) 2000-05-12
ES2169566T3 (es) 2002-07-01
IL136101A0 (en) 2001-05-20
DE59802473D1 (de) 2002-01-24
EP1032379A1 (de) 2000-09-06
SK284338B6 (sk) 2005-02-04
NO20002487L (no) 2000-07-18
PL340631A1 (en) 2001-02-12
HU226592B1 (en) 2009-04-28
IS5484A (is) 2000-05-09
SK7082000A3 (en) 2001-06-11
CZ299116B6 (cs) 2008-04-30
EP1032379B1 (de) 2001-12-12
CA2311128C (en) 2008-01-29
KR20010032229A (ko) 2001-04-16
ATE210438T1 (de) 2001-12-15
KR100534511B1 (ko) 2005-12-08
HUP0004375A3 (en) 2006-06-28
DE19881737D2 (de) 2001-03-22
BR9814214B1 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
DK1032379T3 (da) Præparat med azelainsyre
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
BR9916694A (pt) Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
DK261490D0 (da) New pharmaceutical compound
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
TR200000349T2 (tr) Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
PT1208078E (pt) Sais nao higroscopicos de substancias activas com actividades terapeuticas e/ou nutricionais e composicoes passiveis de serem administradas oralmente contendo os mesmos
MY129121A (en) Composition with azelaic acid
WO2000010590A3 (en) Cancer treatment
FR2547730B1 (fr) Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie
BR9708037A (pt) Método para o tratamento de abuso de substância
ES283591Y (es) Una tableta de dosificacion farmaceutica adecuada para administracion oral
EA199800953A1 (ru) Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
SE9902674D0 (sv) New composition
DE60217302D1 (de) Erhaltung von körpereigenen proteinen
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
EP1106177A4 (en) AGENTS FOR INCREASING MEDICINE ACCUMULATION IN TUMOR TISSUES